KATHRYN BREIHAN: Open Payments
NPI 1376917286 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,183 in 52 payments from 12 companies in 2025. Trend: 2023 $471 · 2024 $881 · 2025 $1,183
Food & beverage: $1,183
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 22 | $411 |
| Lilly USA, LLC | 8 | $266 |
| ABBVIE INC. | 6 | $205 |
| Dexcom, Inc. | 4 | $86 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| PFIZER INC. | 2 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $30 |
| TMS NeuroHealth Centers Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Amgen Inc. | 1 | $20 |
Products named: Ozempic, MAVYRET, ZEPBOUND, Dexcom G6 Transmitter, QULIPTA, MOUNJARO, Rybelsus, AIRSUPRA.
Industry payments across TX — which companies pay providers there.
